Klaria Pharma extends its 147.6 million SEK rights issue subscription period to November 6, 2026, after securing 2.2 million SEK in additional commitments from investors.
Klaria announced extended subscription commitments and extended subscription period for its rights issue, indicating continued investor interest but also potential dilution.
Klaria Pharma Holding AB has extended its rights issue subscription period until November 6, 2026, citing strong investor interest. The company also secured an additional 2.2 million SEK in subscription commitments, bolstering its ongoing capital raise of up to 147.6 million SEK.
The board decided to extend the period due to high interest from shareholders and investors who requested more time to participate in the rights issue.
The rights issue aims to raise up to approximately 147.6 million SEK.